CyFlow™ Kappa-LC FITC
| Antigen: | κ light chains |
| Application: | Flow cytometry |
| Clonality: | monoclonal |
| Clone: | TB28-2 |
| Emission Maximum: | 518 nm |
| Excitation Maximum: | 490 to 495 nm |
| Field of Interest: | Immunoglobulins |
| Format/Fluorochrome: | FITC |
| Isotype: | IgG1 |
| Laser: | Blue |
| Regulatory Status: | CE IVD |
| Source Species: | Mouse |
| Target Species: | Human |
| Product number: | BR896976 |
CE IVD
| Concentration Unit | µg/mL |
| Concentration | 80 |
| Quantity | 100 tests |
| Volume | 1.0 mL |
| Immunogen | Human IgG-κ myeloma protein |
| Background Information | Immunoglobulin classes share the same basic four polypeptide chain structure of two heavy chains (five heavy chains types) and two light chains (κ and λ; both having a molecular weight of 22.5 kDa). κ and λ consist of a variable region and a constant region and can easily be differentiated by the antigenic properties of the constant region. The ratio of κ to λ is 60:40. |
| Antigen Distribution | Immunoglobulin classes share the same basic four polypeptide chain structure of two heavy chains (five heavy chains types) and two light chains (κ and λ; both having a molecular weight of 22.5 kDa). κ and λ consist of a variable region and a constant region and can easily be differentiated by the antigenic properties of the constant region. The ratio of κ to λ is 60:40. |
| Usage | CE IVD usage Placeholder |
| Storage Buffer | The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide and 0.2% (w/v) BSA. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| Kiyotaki M, Cooper MD, Bertoli LF, Kearney JF, Kubagawa H: Monoclonal anti‑Id antibodies react with varying proportions of human B lineage cells. J Immunol. 1987 Jun 15; 138(12):4150‑8. < PMID: 3495581 > | Nakamura T, Kubagawa H, Cooper MD: Heterogeneity of immunoglobulin‑associated molecules on human B cells identified by monoclonal antibodies. Proc Natl Acad Sci USA. 1992 Sep 15; 89(18):8522‑6. < PMID: 1382292 > | Karandikar NJ, Aquino DB, McKenna RW, Kroft SH: Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome: An immunophenotypic analysis. Am J Clin Pathol. 2001 Aug; 116(2):204‑10. < PMID: 11488066 > | Böttcher S, Ritgen M, Buske S, Gesk S, Klapper W, Hoster E, Hiddemann W, Unterhalt M, Dreyling M, Siebert R, Kneba M, Pott C: EU MCL MRD Group: Minimal residual disease detection in mantle cell lymphoma: methods and significance of four‑color flow cytometry compared to consensus IGH‑polymerase chain reaction at initial staging and for follow‑up examinations. Haematologica. 2008 Apr; 93(4):551‑9. < PMID: 18379010 > | Jourdan M, Caraux A, De Vos J, Fiol G, Larroque M, Cognot C, Bret C, Duperray C, Hose D, Klein B: An in vitro model of differentiation of memory B cells into plasmablasts andplasma cells including detailed phenotypic and molecular characterization. Blood. 2009 Dec 10; 114(25):5173‑81. < PMID: 19846886 > | Ildikó Frigyesi, Jörgen Adolfsson, Mina Ali, Mikael Kronborg Christophersen, Ellinor Johnsson, Ingemar Turesson, Urban Gullberg, Markus Hansson, Björn Nilsson: Robust isolation of malignant plasma cells in multiple myeloma. Blood. 2014 Feb 27; 123(9):1336‐1340. < PMID: 24385542 >